NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD
31.98
+1.72 (+5.68%)
The current stock price of KNSA is 31.98 USD. In the past month the price increased by 14.71%. In the past year, price increased by 27.36%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.43 | 344.84B | ||
AMGN | AMGEN INC | 14.3 | 159.64B | ||
GILD | GILEAD SCIENCES INC | 14.62 | 140.79B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.67B | ||
REGN | REGENERON PHARMACEUTICALS | 12.25 | 60.34B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 52.39B | ||
ARGX | ARGENX SE - ADR | 72.69 | 41.24B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.68 | 32.36B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.80B | ||
INSM | INSMED INC | N/A | 20.62B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.10B | ||
BIIB | BIOGEN INC | 8.24 | 19.33B |
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.
KINIKSA PHARMACEUTICALS INTE
23 Old Bond Street, Floor 3
London HM11 GB
CEO: Sanj K. Patel
Employees: 315
The current stock price of KNSA is 31.98 USD. The price increased by 5.68% in the last trading session.
The exchange symbol of KINIKSA PHARMACEUTICALS INTE is KNSA and it is listed on the Nasdaq exchange.
KNSA stock is listed on the Nasdaq exchange.
12 analysts have analysed KNSA and the average price target is 39.37 USD. This implies a price increase of 23.11% is expected in the next year compared to the current price of 31.98. Check the KINIKSA PHARMACEUTICALS INTE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
KINIKSA PHARMACEUTICALS INTE (KNSA) has a market capitalization of 2.37B USD. This makes KNSA a Mid Cap stock.
KINIKSA PHARMACEUTICALS INTE (KNSA) currently has 315 employees.
KINIKSA PHARMACEUTICALS INTE (KNSA) has a support level at 28.61. Check the full technical report for a detailed analysis of KNSA support and resistance levels.
The Revenue of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 34.22% in the next year. Check the estimates tab for more information on the KNSA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KNSA does not pay a dividend.
KINIKSA PHARMACEUTICALS INTE (KNSA) will report earnings on 2025-10-21.
The PE ratio for KINIKSA PHARMACEUTICALS INTE (KNSA) is 799.5. This is based on the reported non-GAAP earnings per share of 0.04 and the current share price of 31.98 USD. Check the full fundamental report for a full analysis of the valuation metrics for KNSA.
The outstanding short interest for KINIKSA PHARMACEUTICALS INTE (KNSA) is 6.22% of its float. Check the ownership tab for more information on the KNSA short interest.
ChartMill assigns a technical rating of 9 / 10 to KNSA. When comparing the yearly performance of all stocks, KNSA is one of the better performing stocks in the market, outperforming 82.59% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to KNSA. KNSA has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months KNSA reported a non-GAAP Earnings per Share(EPS) of 0.04. The EPS increased by 125% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -2.83% | ||
ROE | -3.71% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 87% to KNSA. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 221.23% and a revenue growth 34.22% for KNSA